SecBot SecBot
SECBOTREPLAY Home › Report › CHE

CHE · Chemed reported Q2 2026 GAAP EPS of $5.13 (up 43.7% YoY) and revenue of…

Chemed Corp. · PRESS-RELEASE filed Jul 28, 2026 at 16:15 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jul 28, 2026 at 16:15 ET

Chemed reported Q2 2026 GAAP EPS of $5.13 (up 43.7% YoY) and revenue of $673.3M (up 8.8% YoY), beating consensus estimates of $5.60 EPS and $665.0M revenue by 0.9% and 1.2%, respectively. The beat was driven by VITAS's strong performance, with revenue up 11.9% and a sharp reduction in Medicare Cap billing limitations ($0.5M vs $16.4M last year). Guidance was raised meaningfully, with full-year adjusted EPS now $25.00-$25.75 (up from $24.00-$24.75), and VITAS ADC/revenue growth and EBITDA margin targets all revised upward, making this a clear bullish catalyst.

  • Revenue $673.3M (+8.8% YoY) vs consensus $665.0M
  • GAAP diluted EPS $5.13 (+43.7% YoY) vs consensus $5.60
  • Adjusted diluted EPS $6.06 (+41.9% YoY)
  • VITAS net revenue $443.3M (+11.9% YoY), ADC up 6.1% to 23,687

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access